Insomnia News and Research

Latest Insomnia News and Research

Cephalon receives FDA Complete Response Letter for NUVIGIL supplemental new drug application

Cephalon, Inc. today announced the company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for its supplemental new drug application for NUVIGIL® (armodafinil) Tablets [C-IV] in the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel.

30 Mar 2010

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has approved once-daily Mirapex ER® (pramipexole dihydrochloride) extended-release tablets for the signs and symptoms of idiopathic Parkinson's disease, which includes early and advanced PD. PD is the second most common chronic neurological disorder in older adults after Alzheimer's. Parkinson's disease has no cure.

26 Mar 2010

Clinical Data completes NDA submission for vilazodone

Clinical Data, Inc., today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vilazodone for the treatment of major depressive disorder (MDD). Vilazodone is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. The Company expects that the NDA submission, if accepted, will be subject to a standard review.

23 Mar 2010

Somaxon Pharmaceuticals to sell 4 million common stock shares

Somaxon Pharmaceuticals, Inc. today announced that it is offering to sell up to 4,000,000 shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in the offering. The co-manager in the offering is Oppenheimer & Co. Inc. Somaxon expects to grant the underwriters an option to purchase up to an additional 600,000 shares of common stock to cover overallotments of shares, if any.

23 Mar 2010

LPI's ANDA for Eszopiclone tablets receives tentative approval from USFDA

Lupin Pharmaceuticals, Inc. announced today that it has received tentative approval for the Company's Abbreviated New Drug Application for Eszopiclone tablets, 1 mg, 2 mg and 3 mg from the U.S. Food and Drug Administration.

23 Mar 2010

Acorda Therapeutics submits applications to extend patent protection for AMPYRA to USPTO

Acorda Therapeutics, Inc. today announced that the Company has submitted applications to extend patent protection for AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg to the United States Patent and Trademark Office.

22 Mar 2010

InvestorSoup.com announces investment report featuring Somaxon Pharmaceuticals

InvestorSoup.com announces an investment report featuring Somaxon Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

19 Mar 2010

FDA approves Somaxon Pharmaceuticals' Silenor for treatment of insomnia

Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.

19 Mar 2010

CNS Network purchases Logos Technologies' pro-active EDC system for streamlining clinical trials

It is announced today that CNS Network has purchased ALPHADAS®, Logos Technologies Inc’s early phase, e-source data capture system and site automation tools to accelerate and streamline its clinical trials. ALPHADAS is to be implemented in their Orange County Research Center, California, USA.

17 Mar 2010

Sleep deprivation may increase heart attack risk

On average, people go to work or school on the first Monday of Daylight Savings after sleeping 40 fewer minutes than normal. And recent studies have found there's a higher risk of heart attacks, traffic accidents and workplace injuries on the first Monday of Daylight Savings.

11 Mar 2010

Sleep disorders may increase risk of cardiovascular and metabolic diseases

Many Americans will lose an hour of sleep on March 14, the first day of daylight-saving time, when clocks are set ahead one hour at 2 a.m. local standard time—making it harder to wake up, causing difficulty in staying alert and increasing the chance of sleepy-driving car crashes.

11 Mar 2010

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.

9 Mar 2010

NSF's Sleep in America poll finds differences in sleep habits and attitudes among ethnic groups

The 2010 Sleep in America poll released today by the National Sleep Foundation reveals significant differences in the sleep habits and attitudes of Asians, Blacks/African-Americans, Hispanics and Whites. It is the first poll to examine sleep among these four ethnic groups.

8 Mar 2010

Presentation of results from open-label extension study of Xenazine

Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p< 0.0001) as measured using the Unified Huntington's Disease Rating Scale (UHDRS) compared with baseline.

6 Mar 2010

Promises Treatment Center CEO's insights on Redmond O'Neal's addiction and rehabilitation problems

The unfortunate story of Redmond O'Neal continues to make headlines. He has been an admitted addict since he was a teen and has had multiple drug arrests. He recently appeared in court for a status hearing on his latest stint in rehab.

5 Mar 2010

Neurocrine Biosciences to sell common stock shares

Neurocrine Biosciences, Inc. today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is the sole book-running manager for this offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

5 Mar 2010

KAPIDEX to be marketed as DEXILANT in the U.S.

Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX™ (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT™ (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.

5 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Merck & Co., Inc. today announced its updated, newly integrated, late-stage pipeline following its recent merger with Schering-Plough. The new pipeline features a broad and diversified portfolio of investigational medicines and vaccines, including more than 20 candidates in Phase III or under regulatory review, and more than 20 candidates in Phase II of development.

3 Mar 2010

Stanford University Medical Center buys ASTI's Ecotones Duet Adaptive Sleep Sound Machines

Adaptive Sound Technologies, Inc. (ASTI) announced today that the Stanford University Medical Center has purchased Ecotones Duet Adaptive Sleep Sound Machines. "It is well known that noise in hospitals affects patient comfort and recovery, as well as staff performance. ASTI's adaptive technology can help with these problems," stated Sam Nicolino, President and CEO of ASTI.

3 Mar 2010

Insomnia News and Research

Latest Insomnia News and Research

Cephalon receives FDA Complete Response Letter for NUVIGIL supplemental new drug application

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

Clinical Data completes NDA submission for vilazodone

Somaxon Pharmaceuticals to sell 4 million common stock shares

LPI's ANDA for Eszopiclone tablets receives tentative approval from USFDA

Acorda Therapeutics submits applications to extend patent protection for AMPYRA to USPTO

InvestorSoup.com announces investment report featuring Somaxon Pharmaceuticals

FDA approves Somaxon Pharmaceuticals' Silenor for treatment of insomnia

CNS Network purchases Logos Technologies' pro-active EDC system for streamlining clinical trials

Sleep deprivation may increase heart attack risk

Sleep disorders may increase risk of cardiovascular and metabolic diseases

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

NSF's Sleep in America poll finds differences in sleep habits and attitudes among ethnic groups

Presentation of results from open-label extension study of Xenazine

Promises Treatment Center CEO's insights on Redmond O'Neal's addiction and rehabilitation problems

Neurocrine Biosciences to sell common stock shares

KAPIDEX to be marketed as DEXILANT in the U.S.

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Stanford University Medical Center buys ASTI's Ecotones Duet Adaptive Sleep Sound Machines

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Insomnia News and Research

Latest Insomnia News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in